Perioperative chemotherapy for upper tract urothelial cancer

Nature Reviews Urology

Volumn 9, Issue 5, 2012, Pages 266-273

  Alva, Ajjai S ^a   Matin, Surena F ^b   Lerner, Seth P ^c   Siefker Radtke, Arlene O ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; METHOTREXATE; PACLITAXEL; VINBLASTINE;

BLADDER BIOPSY; BLADDER SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DISEASE SPECIFIC SURVIVAL; ENDOSCOPIC BIOPSY; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; JAPAN; KOREA; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST TREATMENT SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; HUMANS; KIDNEY NEOPLASMS; PREOPERATIVE CARE; URETERAL NEOPLASMS;

EID: 84862216793     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2012.57     Document Type: Review

References (101)

1. Tawfiek, E. R. & Bagley, D. H. Upper-tract transitional cell carcinoma. Urology 50, 321-329 (1997
2. Munoz, J. J. & Ellison, L. M. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J. Urol. 164, 1523-1525 (2000
3. Konety, B. R., Joyce, G. F. & Wise, M. Bladder and upper tract urothelial cancer. J. Urol. 177, 1636-1645 (2007
4. Lughezzani, G. et al. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur. J. Cancer 45, 3291-3297 (2009
5. Margulis, V. et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115, 1224-1233 (2009
6. Latini, D. et al. Upper tract urothelial cancer: a descriptive analysis using SEER data, 1973-2003. Presented at the Genitourinary Cancers Symposium 2008 (abstract no. 305
7. Kaag, M. G. et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur. Urol. 58, 581-587 (2010
8. Catto, J. W. et al. Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J. Urol. 175, 2323-2330 (2006
9. Catto, J. W. et al. Behavior of urothelial carcinoma with respect to anatomical location. J. Urol. 177, 1715-1720 (2007
10. Zhang, Z., Furge, K. A., Yang, X. J., Teh, B. T. & Hansel, D. E. Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. BMC Med. Genomics 3, 58 (2010
11. Tsai, Y. S., Tzai, T. S., Chow, N. H. & Wu, C. L. Frequency and clinicopathologic correlates of ErbB1, ErbB2, and ErbB3 immunoreactivity in urothelial tumors of upper urinary tract. Urology 66, 1197-1202 (2005
12. Eltz, S., Comperat, E., Cussenot, O. & Roupret, M. Molecular and histological markers in urothelial carcinomas of the upper urinary tract. BJU Int. 102, 532-535 (2008
13. Hafner, C. et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene 20, 4910-4915 (2001
14. Roscigno, M. et al. Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology 74, 1070-1074 (2009
15. Roscigno, M. et al. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J. Urol. 181, 2482-2489 (2009
16. Roscigno, M. et al. The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur. Urol. 56, 512-518 (2009
17. Keeley, F. X., Kulp, D. A., Bibbo, M., McCue, P. A. & Bagley, D. H. Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma. J. Urol. 157, 33-37 (1997
18. Williams, S. K. et al. Correlation of upper-tract cytology, retrograde pyelography, ureteroscopic appearance, and ureteroscopic biopsy with histologic examination of upper-tract transitional cell carcinoma. J. Endourol. 22, 71-76 (2008
19. Brown, G. A. et al. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology 70, 252-256 (2007
20. Skolarikos, A. et al. Cytologic analysis of ureteral washings is informative in patients with grade 2 upper tract TCC considering endoscopic treatment. Urology 61, 1146-1150 (2003
21. Capitanio, U. et al. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur. Urol. 56, 1.9 (2009
22. Favaretto, R. L. et al. Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? Eur. Urol. 58, 645.651 (2010
23. McNeill, S. A., Chrisofos, M. & Tolley, D. A. The long-term outcome after laparoscopic nephroureterectomy: a comparison with open nephroureterectomy. BJU Int. 86, 619.623 (2000
24. Rassweiler, J. J. et al. Laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: is it better than open surgery? Eur. Urol. 46, 690.697 (2004
25. Simone, G. et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study. Eur. Urol. 56, 520.526 (2009
26. Messer, J., Lin, Y. K. & Raman, J. D. The role of lymphadenectomy for upper tract urothelial carcinoma. Nat. Rev. Urol. 8, 394.401 (2011
27. Karl, A. et al. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur. Urol. 55, 826.835 (2009
28. Kirkali, Z. & Tuzel, E. Transitional cell carcinoma of the ureter and renal pelvis. Crit. Rev. Oncol. Hematol. 47, 155.169 (2003
29. Brown, G. A. et al. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int. 98, 1176.1180 (2006
30. Cozad, S. C. et al. Transitional cell carcinoma of the renal pelvis or ureter: patterns of failure. Urology 46, 796.800 (1995
31. Cozad, S. C. et al. Adjuvant radiotherapy in high stage transitional cell carcinoma of the renal pelvis and ureter. Int. J. Radiat. Oncol. Biol. Phys. 24, 743.745 (1992
32. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361, 1927.1934 (2003
33. Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859.866 (2003
34. Tannock, I., Gospodarowicz, M., Connolly, J. & Jewett, M. MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J. Urol. 142, 289.292 (1989
35. Lerner, S. E., Blute, M. L., Richardson, R. L. & Zincke, H. Platinum-based chemotherapy for advanced transitional cell carcinoma of the upper urinary tract. Mayo Clin. Proc. 71, 945.950 (1996
36. Sternberg, C. N. et al. M.VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J. Urol. 139, 461.469 (1988
37. Loehrer, P. J. et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10, 1066.1073 (1992
38. Bamias, A. et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J. Clin. Oncol. 22, 220.228 (2004
39. Kaufman, D. S. et al. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol. Oncol. 22, 393.397 (2004
40. Czito, B., Zietman, A., Kaufman, D., Skowronski, U. & Shipley, W. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J. Urol. 172, 1271.1275 (2004
41. Kwak, C., Lee, S. E., Jeong I. G. & Ku, J. H. Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology 68, 53.57 (2006
42. Lee, S. E. et al. Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract. Urol. Int. 77, 22.26 (2006
43. Soga, N., Arima, K. & Sugimura, Y. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int. J. Urol. 15, 800.803 (2008
44. Hellenthal, N. J. et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J. Urol. 182, 900.906 (2009
45. Vassilakopoulou, M. et al. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer 117, 5500.5508 (2011
46. Bamias, A. et al. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J. Clin. Oncol. 22, 2150.2154 (2004
47. Bellmunt, J. et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80, 1966.1972 (1997
48. Dreicer, R. et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100, 1639.1645 (2004
49. Petrioli, R. et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 77, 344.351 (1996
50. Dogliotti, L. et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur. Urol. 52, 134.141 (2007
51. Lane, B. R. et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 116, 2967.2973 (2010
52. Ku, J. H., Choi, W. S., Kwak, C. & Kim, H. H. Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract. Urol. Oncol. 29, 383.387 (2011
53. Azemar, M. D., Comperat, E., Richard, F., Cussenot, O. & Roupret, M. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. Urol. Oncol. 29, 130.136 (2011
54. Hall, M. C., Womack, J. S., Roehrborn, C. G., Carmody, T. & Sagalowsky, A. I. Advanced transitional cell carcinoma of the upper urinary tract: patterns of failure, survival and impact of postoperative adjuvant radiotherapy. J. Urol. 160, 703.706 (1998
55. Hisataki, T. et al. Risk factors for the development of bladder cancer after upper tract urothelial cancer. Urology 55, 663.667 (2000
56. Koda, S., Mita, K., Shigeta, M. & Usui, T. Risk factors for intravesical recurrence following urothelial carcinoma of the upper urinary tract: no relationship to the mode of surgery. Jpn J. Clin. Oncol. 37, 296.301 (2007
57. Shikanov, S. et al. Vesical vs. extra-vesical patterns of recurrence after the treatment of urothelial upper tract tumors. Urol. Oncol. 26, 266.270 (2008
58. Takaoka, E. et al. Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: a single institutional retrospective long-term follow-up study. Int. J. Urol. 17, 623.628 (2010
59. Zigeuner, R. E., Hutterer, G., Chromecki, T., Rehak, P. & Langner, C. Bladder tumor development after urothelial carcinoma of the upper urinary tract is related to primary tumor location. BJU Int. 98, 1181.1186 (2006
60. Raman, J. D. et al. Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology. BJU Int. 96, 1031.1035 (2005
61. Terakawa, T. et al. Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. Urology 71, 123.127 (2008
62. O'Brien, T. et al. Prevention of bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicenter, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT.C trial). Eur. Urol. 60, 703.710 (2011
63. International collaboration of trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party et al. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354, 1650 (1999
64. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48, 202.206 (2005
65. Splinter, T. A., Denis, L., Scher, H. I., Schroder, F. H. & Dalesio, O. Neoadjuvant chemotherapy of invasive bladder cancer. The prognostic value of local tumor response. Prog. Clin. Biol. Res. 303, 541.547 (1989
66. Matin, S. F. et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116, 3127.3134 (2010
67. Igawa, M. et al. Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. Urol. Int. 55, 74.77 (1995
68. Siefker.Radtke, A. O. et al. A phase II trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine (IAG), followed by cisplatin, gemcitabine and ifosfamide (CGI) in locally advanced urothelial cancer (UC): final results from the M. D. Anderson Cancer Center. J. Clin. Oncol. 26, 5079 (2008
69. Palapattu, G. S. et al. Cancer specific outcomes in patients with pT0 disease following radical cystectomy. J. Urol. 175, 1645-1649 (2006
70. Tilki, D. et al. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J. Urol. 184, 888-894 (2010
71. Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666-675 (2001
72. Hall, M. C., Swanson, D. A. & Dinney, C. P. Complications of radical cystectomy: impact of the timing of perioperative chemotherapy. Urology 47, 826-830 (1996
73. Millikan, R. et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J. Clin. Oncol. 19, 4005-4013 (2001
74. Rajput, M. Z. et al. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology 78, 68-71 (2011
75. Sundi, D. et al. Upper tract urothelial carcinoma: Impact of time to surgery. Urol. Oncol. http://dx.doi.org/10.1016/j.urolonc.2010.04.002.
76. Gadzinski, A. J., Roberts, W. W., Faerber, G. J. & Wolf, J. S. Long-term outcomes of immediate versus delayed nephroureterectomy for upper tract urothelial carcinoma. J. Endourol. .
77. Vassilakopoulou, M. et al. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer 117, 5500-5508 (2011
78. Hall, M. C. et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52, 594-601 (1998
79. Shariat, S. F. et al. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. BJU Int. 105, 1672-1677 (2010
80. Cho, K. S., Hong, S. J., Cho, N. H. & Choi, Y. D. Grade of hydronephrosis and tumor diameter as preoperative prognostic factors in ureteral transitional cell carcinoma. Urology 70, 662-666 (2007
81. Lehmann, J. et al. Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival. Eur. Urol. 51, 1281-1288 (2007
82. Olgac, S., Mazumdar, M., Dalbagni, G. & Reuter, V. E. Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am. J. Surg. Pathol. 28, 1545-1552 (2004
83. Simone, G. et al. Independent prognostic value of tumor diameter and tumor necrosis in upper urinary tract urothelial carcinoma. BJU Int. 103, 1052-1057 (2009
84. Brien, J. C. et al. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J. Urol. 184, 69-73 (2010
85. Ito, Y. et al. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J. Urol. 185, 1621-1626 (2011
86. Ng, C. K. et al. Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma? Urol. Oncol. 29, 27-32 (2011
87. Fritsche, H. M. et al. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol. Oncol. .
88. Remzi, M. et al. Tumor architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int. 103, 307-311 (2009
89. Langner, C. et al. Tumor necrosis as prognostic indicator in transitional cell carcinoma of the upper urinary tract. J. Urol. 176, 910-914 (2006
90. Seitz, C. et al. Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study. J. Urol. 184, 1895-1900 (2010
91. Zigeuner, R. et al. Tumor necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur. Urol. 57, 575-581 (2010
92. Guo, C. C., Tamboli, P. & Czerniak, B. Micropapillary variant of urothelial carcinoma in the upper urinary tract: a clinicopathologic study of 11 cases. Arch. Pathol. Lab. Med. 133, 62-66 (2009
93. Holmang, S., Thomsen, J. & Johansson, S. L. Micropapillary carcinoma of the renal pelvis and ureter. J. Urol. 175, 463-467 (2006
94. Perez-Montiel, D., Hes, O., Michal, M. & Suster, S. Micropapillary urothelial carcinoma of the upper urinary tract: clinicopathologic study of five cases. Am. J. Clin. Pathol. 126, 86-92 (2006
95. Bolenz, C. et al. Lymphovascular invasion and pathologic tumor stage are significant outcome predictors for patients with upper tract urothelial carcinoma. Urology 72, 364-369 (2008
96. Kikuchi, E. et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J. Clin. Oncol. 27, 612-618 (2009
97. Kim, D. S. et al. Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma. Urology 75, 328-332 (2010
98. Novara, G. et al. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur. Urol. 57, 1064-1071 (2010
99. Chromecki, T. F. et al. The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur. Urol. 61, 245-253 (2012
100. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00696007 (2012
101. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01261728?term=NCT01261728&rank=1 (2012)